報價延遲最少15分鐘:2026/10/18 16:51 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.02 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.96/-1.25
|
|
企業價值
11.62M
|
| 資產負債 |
|
每股賬面淨值
3.75
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
13.19M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. It is also developing, dependent on resources for development activities, MC1R agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It has one operating segment life science. |
